

1 **Title**

2 Increase in ventilatory ratio indicates progressive alveolar damage and suggests poor
3 prognosis in severe COVID-19: A single-center retrospective observational study.

4 **Authors**

5 Natsuko Kaku ^{1,4}, kaku.natsuko@med.osaka-cu.ac.jp

6 Yu Nakagama ¹, nakagama.yu@med.osaka-cu.ac.jp

7 Michinori Shirano ³, shirano@wonder.ocn.ne.jp

8 Sari Shinomiya ⁴, sallyshinomiya@gmail.com

9 Kazuhiro Shimazu ⁴, kazuhiro.shimazu.0211@gmail.com

10 Katsuaki Yamazaki ⁵, ymzk_ktak@yahoo.co.jp

11 Yoshito Maehata ⁴, yoppymae@yahoo.co.jp

12 Ryo Morita ³, ryo10071007mrt@yahoo.co.jp

13 Yuko Nitahara ¹, yuko.nitahara74@gmail.com

14 Hiromasa Yamamoto ², hyamamoto@med.osaka-cu.ac.jp

15 Yasumitsu Mizobata ², mizobata@med.osaka-cu.ac.jp

16 Yasutoshi Kido ¹, kido.yasutoshi@med.osaka-cu.ac.jp

17 **Institution addresses**

18 ¹ Department of Parasitology, Research Center for Infectious Disease Sciences,

19 ² Department of Traumatology and Critical Care Medicine,

20 Graduate School of Medicine, Osaka City University

21 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585 Japan

22 ³ Department of Infectious Diseases,

23 ⁴ Department of Anesthesia and Intensive Care Medicine,

24 Osaka City General Hospital, Osaka City Hospital Organization

25 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka 534-0021 Japan

26 ⁵ Department of Anesthesiology, National Cerebral and Cardiovascular Center Hospital

27 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565 Japan

28 **Corresponding author** Yasutoshi Kido, kido.yasutoshi@med.osaka-cu.ac.jp

29 **Abstract (347 words)**

30 **Background:** The symptoms of severe COVID-19 are complex and wide-ranging even in

31 intensive care unit (ICU) patients, who may successfully discontinue respiratory support in a

32 short period or conversely require prolonged respiratory support. Damage in the lungs of

33 COVID-19 patients is characterized pathologically as diffuse alveolar damage, the degree of

34 which correlates with the severity of the disease. We hypothesized that the ventilatory ratio

35 (VR), a surrogate parameter for the dead space fraction, might stratify the severity of COVID-

36 19 and predict the successful discontinuation of respiratory support.

37 **Methods:** Forty COVID-19 patients in our ICU were enrolled in this study. Respiratory
38 variables were collected from 2 hours (day 0) after the initiation of respiratory support. We
39 monitored the longitudinal values of VR and other respiratory parameters for 28 days.
40 Patients successfully discontinued from respiratory support by day 28 of ICU stay were
41 defined as the successfully discontinued group, while those who died or failed to discontinue
42 were defined as the failed to discontinue group. VR and other respiratory parameters were
43 compared between these groups.

44 **Results:** Except for advanced age, prolonged ventilation period, and higher mortality in the
45 failed to discontinue group, there were no significant differences between the groups in terms
46 of any other background or respiratory parameter at 2 hours (day 0) after initiation of
47 respiratory support. Longitudinal VR monitoring revealed significantly higher VR values in
48 the failed to discontinue group than the successfully discontinued group on day 4 of
49 respiratory support. Upon predicting the failure to discontinue respiratory support, the area
50 under the receiver operating characteristic curve of VR values on day 4 of respiratory support
51 was 0.748. A threshold of 1.56 achieved the highest predictive performance with a sensitivity
52 of 0.667 and a specificity of 0.762. This threshold enabled the prediction of the successfully
53 discontinued outcome at 0.810 of the negative predictive value.

54 **Conclusions:** Elevated VR values on day 4 of respiratory support were predictive of successful

55 discontinuation of respiratory support in patients with severe COVID-19. Longitudinal VR
56 values after initiation of respiratory support can be used as a practical index to stratify severe
57 COVID-19.

58 **Keywords:** severe COVID-19, SARS-CoV-2, ARDS, ventilatory ratio, dead space, alveolar
59 damage

60 **Background**

61 COVID-19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2
62 (SARS-CoV-2), that emerged at the end of 2019, has a broad spectrum of manifestations from
63 asymptomatic to critical illness. Even in the case of critically ill patients who are admitted to
64 intensive care units (ICUs), some improve after only a few days of respiratory support,
65 whereas others require prolonged respiratory support resulting in poor prognosis.

66 Similar to other lethal human coronaviruses such as SARS-CoV and MERS-CoV, the SARS-
67 CoV-2 virus enters host cells, harnessing its spike protein to angiotensin-converting enzyme
68 2 (ACE2) receptor on the surface of the host cell (1). ACE2 is highly expressed in lung alveolar
69 cells and bronchial epithelium, where the virus enters initially and proliferates (2). Therefore,
70 the principal pathological manifestation of COVID-19 is considered to be alveolar damage,
71 and the severity may depend on the progress of diffuse alveolar damage (DAD) (3,4) which
72 is a typical feature of acute respiratory distress syndrome (ARDS) (5). However, the lack of

73 appropriate indices for real-time monitoring of DAD is currently limiting stratification of
74 patients who are critically ill with COVID-19.

75 DAD reduces effective gas exchange between alveolar epithelial cells and the pulmonary
76 capillaries, thus increasing the functional dead space. Dead space fraction (V_D/V_T) is the most
77 crucial factor dictating respiratory adequacy. Several studies have demonstrated the
78 importance of V_D/V_T in ARDS patients, in terms of both prognostication and disease
79 progression (6). Despite its effectiveness, V_D/V_T is seldom measured in usual ICU practice
80 because of the complexity of calculation and the associated equipment costs (6).

81 Ventilatory ratio (VR) is a simple bedside index that has recently been proposed as a surrogate
82 parameter for V_D/V_T (6,7). It is easily calculated using minute ventilation and arterial partial
83 pressure of carbon dioxide ($PaCO_2$), as follows (8):

$$84 \quad [\text{minute ventilation (mL)} \times PaCO_2 \text{ (mmHg)}] / \text{predicted body weight} \times 100 \times 37.5.$$

85 Sinha et al. have reported high VR as an independent predictor of mortality in two distinct
86 ARDS randomized controlled trials (9,10), and have confirmed a significant correlation
87 between VR and V_D/V_T in ARDS (8).

88 Therefore, we monitored longitudinal VR in patients with severe COVID-19 who required
89 respiratory support in our ICU with the aim of determining whether VR could stratify the
90 severity of COVID-19 and predicting successfully discontinued prognosis.

91 **Methods**

92 **Study design**

93 This is a retrospective, single-center, observational study that enrolled patients with severe
94 COVID-19 admitted into our ICU from February 29 to November 20, 2020. To identify the
95 relationship between patient characteristics and prolonged respiratory support, the patients
96 were stratified into two groups based on respiratory support dependency for the observed 28
97 days because the failure to discontinue respiratory support during the initial 28 days is known
98 to have a strong correlation with mortality (11). In the observation period, patients who could
99 not discontinue respiratory support were included to the failed to discontinue group and
100 patients who could successfully discontinue respiratory support were included to the
101 successfully discontinued group.

102 **Data collection**

103 Data from patients' electronic medical records were collected and reviewed by physicians
104 trained in critical care. The inclusion criteria were age \geq 18 years; SARS-CoV-2 infection
105 confirmed by PCR or antigen test; and ICU admission for respiratory support, defined as the
106 use of invasive mechanical ventilation. Of 45 eligible patients, 5 who were not ventilated at
107 our hospital were excluded, and a total of 40 patients were included in the study.
108 The recorded data included patients demographics (age, gender, body mass index (BMI),

109 comorbidities), disease course (days from onset to O₂ requirement, days from onset to
110 respiratory support, days of respiratory support, ICU mortality), laboratory and ventilatory
111 parameters (minute ventilation (MV), tidal volume (TV), set PEEP, plateau pressure (P_{plat}),
112 static lung compliance (C_{stat}), PaCO₂, PaCO₂/FiO₂ (P/F) ratio, and VR). A complete data
113 set was obtained 2 hours (day 0) after the patients was placed on respiratory support. VR and
114 C_{stat} were calculated as follows:

$$115 \quad VR = (MV \text{ [mL]} \times PaCO_2 \text{ [mmHg]}) / (\text{predicted body weight [kg]} \times 100 \text{ [mL/kg]} \times 37.5 \\ 116 \quad \text{[mmHg]})$$

$$117 \quad C_{stat} \text{ [mL/cmH}_2\text{O]} = TV \text{ [mL]} / (P_{plat} \text{ [cmH}_2\text{O]} - PEEP \text{ [cmH}_2\text{O]})$$

118 **Statistical analysis**

119 All analyses were performed with GraphPad Prism 9.1.1 (GraphPad Software, Inc., San Diego,
120 CA). Variables were compared between the groups using Mann-Whitney test for continuous
121 variables and Chi-square test for binary data. To assess differences in longitudinal VR and its
122 factors between the groups, VR values after starting respiratory support were plotted and
123 analyzed by Mann-Whitney test. To validate whether the increased VR can become a
124 prognostic index for successfully discontinued from respiratory support in severe COVID-19,
125 we performed receiver operating characteristic (ROC) curves analysis of VR values on days
126 0-4 after respiratory support. All time points to events were defined from 2 hours (day 0) after

127 initiation of invasive respiratory support. Missing data were not imputed. Days of respiratory
128 support of patients who prolonged respiratory support longer than the observation period
129 were deemed 28. Descriptive variables were expressed as the percentage or median and
130 interquartile range (IQR), as appropriate. All tests were two-sided, and a p -value < 0.05 was
131 considered statistically significant.

132 **Results**

133 Among 45 patients admitted to our ICU between 29 Feb and 20 Nov 2020, 40 patients who
134 met the inclusion criteria were enrolled in this study and followed for at least 28 days. The
135 patient demographics, disease course, laboratory and respiratory parameters are listed in
136 Table 1. Time from symptom onset to initiation of oxygen therapy was 7 days (IQR: 6–9
137 days) and that to initiation of respiratory support was 8 days (IQR: 7–10 days). Extraordinary
138 short interval of 1 day from oxygen therapy to respiratory support indicates a rapid worsening
139 of hypoxemia in COVID-19. The duration of respiratory support was 11 days (IQR: 5–18
140 days), and the overall mortality rate in ICU was 25.0%. Days of respiratory support were 19
141 vs 7 days and ICU mortality was 71.4% vs 0.0% in the failed to discontinue and successfully
142 discontinued groups, respectively (significant difference, both p -value < 0.001).
143 Age was significantly greater in the failed to discontinue group than the successfully
144 discontinued group (median, 75 vs 67 years respectively, p -value = 0.027). There was a

145 predominance of males (34/40, 85.0%). Median BMI was 25 kg/m² (IQR, 22–29 kg/m²).

146 The incidence of the comorbidities of diabetes (18/40, 45.0%) and hypertension (21/40,

147 52.5%) in all patients in the study were higher than the prevalence in Japanese men (13.8%

148 and 23.0%, respectively adjusted by age)(12).

149 The median values of respiratory parameters at 2 hours (day 0) after initiation of respiratory

150 support in all patients were as follows: MV, 8.0 L (IQR, 6.3–9.0 L); TV, 7.2 mL/kg (IQR,

151 6.2–7.9 mL/kg); set PEEP, 9.0 cmH₂O (IQR, 7.3–10.0 cmH₂O); and Pplat, 22.0 cmH₂O

152 (IQR, 20.0–25.0 cmH₂O). Lung static compliance was 33.3 mL/mmH₂O (IQR, 27.8–44.5

153 mL/mmH₂O), which is slightly lower than the 40 mL/cmH₂O in the Berlin definition (13).

154 PaCO₂ was 41.4 mmHg (IQR, 36.8–49.3 mmHg), and there was no apparent hypercapnia.

155 P/F ratio was 173.5 (IQR, 126.5–248.0), and ARDS was most frequently moderate in

156 severity. VR was 1.5 (IQR, 1.3–2.0), higher than the value of 1. The normal value of VR is

157 around 1, but increases with worsening ventilation mechanics, excess CO₂ production, or both

158 (7). There was no significant difference in any of these respiratory parameters between the

159 two groups.

160 Figure 1 shows the longitudinal VR values from 2 hours (day 0) of respiratory support to day

161 6. VR was stable until around day 2 after initiation of respiratory support in both groups. In

162 the failed to discontinue group, VR increased on day 3. VR was significantly higher in the

163 failed to discontinue group than in the successfully discontinued group on day 4 after
164 respiratory support (p -value = 0.027) (Figure 1a). Throughout the observation period there
165 was no apparent trend in the change in PaCO₂ or MV, which are both used to calculate VR
166 (Figure 1b, c).

167 Figure 2 shows ROC curves for VR on days 0-4 after initiation of respiratory support.
168 Differences in VR values are seen between the two groups with the progression of time. The
169 area under the ROC curve (AUC) maximized on day 4 was 0.748, which indicates moderate
170 accuracy (statistically significant, p -value = 0.019) (Table 2). The cut-off value for maximum
171 diagnostic performance with a sensitivity of 0.667 and a specificity of 0.762 was VR > 1.56.
172 Using VR > 1.56 as the threshold in the present cohort, the failed to discontinue (positive)
173 predictive value was 0.667 (true positive 8 vs false positive 4) and the successfully
174 discontinued (negative) predictive value was 0.810 (true negative 17 vs false negative 4) on
175 day 4.

176 **Discussion**

177 This study monitored longitudinal VR in patients with severe COVID-19 who required
178 respiratory support in our ICU with aim of determining whether VR could stratify the severity
179 of COVID-19 and predicting successfully discontinued prognosis. The main findings were
180 that VR on day 4 after initiation of respiratory support was higher than in the failed to

181 discontinue group than the successfully discontinued group, and that a threshold of VR < 1.56
182 was predictive of successful discontinuation with a predictive value of 0.810.

183 Pulmonary pathology of COVID-19 can be subdivided into four main morphological stages:
184 [1] early stage (day 0 – 1) with edema, incipient epithelial damage, and capillaritis, [2]
185 exudative DAD stage (days 1 – 7), [3] organizing stage (1 to several weeks), and [4] fibrotic
186 DAD stage (weeks to months) (14). Pre-symptomatic histology observed in surgical sections
187 obtained from patients who were later found to have COVID-19 included proteinaceous
188 exudate, focal reactive hyperplasia of pneumocytes, alveolar hemorrhage, and inflammatory
189 cellular infiltration (15,16). Autopsy of acute COVID-19 patients within 20 days from
190 symptom onset revealed exudative DAD, massive capillary congestion, and pulmonary
191 embolism (17). The time point of the increase in VR found in the present study coincides
192 with the stage of exudative DAD. Therefore, the increased VR on day 4 after initiation of
193 respiratory support may indicate the severity of DAD.

194 From the immunological perspective, neutralizing antibody and T-cell responses play
195 essential roles in eliminating SARS-CoV-2 from the body (18,19). In previous studies,
196 patients who experience mild symptoms eliminated the virus within 15 days, whereas patients
197 with moderate and severe symptoms take much longer to eliminate the virus from the upper
198 respiratory tract (18). Peak neutralizing activity of virus-specific antibodies was achieved

199 within 9 – 15 days after symptom onset, and patients with moderate/severe symptoms
200 exhibited more robust responses than those with mild disease. Higher frequencies of IFN- γ -
201 secreting T cells at around day 15 from symptom onset were present in mild, but not in
202 moderate/severe COVID-19 patients (18). Considering interval from symptom onset to
203 respiratory support averaged to 8 days, the time point of the VR increase on day 4 after
204 respiratory support in the failed to discontinue group coincided with the immunological
205 turning point at around days 10–15 from symptom onset. The increased VR on day 4 after
206 respiratory support might reflect the immunological dynamics in patients with severe
207 COVID-19.

208 The ROC curve of VR on day 4 after initiation of respiratory support was predictive of
209 successful discontinuation from respiratory support with a high predictive value in this cohort.

210 Therefore, VR values may indicate the effectiveness of current treatment. Moreover, the
211 stratification of severe COVID-19 according to VR may enable consideration of the
212 appropriate therapy on an individual basis, such as the decision whether to continue with
213 aggressive COVID-19-specific therapies. VR has a potential to be a candidate predictor for
214 improving predictive abilities of current risk prediction models for ICU patients with COVID-
215 19 (20).

216 In contrast to the present study, some previous reports (21–23) that have used VR to assess

217 the clinical condition of patients with COVID-19 have concluded that VR is a minimally useful
218 indicator. The reason for the discrepancy in results may be that these previous studies
219 calculated VR only once, on the day that respiratory support was initiated. As demonstrated
220 in the present study, a significant difference in VR values between the failed to discontinue
221 and successfully discontinued groups was apparent on day 4 after initiation of respiratory
222 support, and the difference was a predictor of successfully discontinued prognosis. VR being
223 an easily calculated bedside friendly parameter, frequent assessment and longitudinal
224 monitoring is feasible and potentially useful in understanding the severity status of COVID-
225 19 patients.

226 This study has some limitations. The most appropriate VR value to be used as the threshold
227 requires further evaluation. This study only used data up to day 6 of respiratory support. Data
228 were not available after day 7 because a large number of patients were withdrawn from
229 respiratory support at the time. Finally, we cannot rule out the possibility of selection bias
230 because we included only a small number of patients collected at a single institution.

231 **Conclusions**

232 Increased VR values on day 4 after initiation of respiratory support is predictive of successful
233 discontinuation in patients with severe COVID-19. Day 4 after respiratory support coincides
234 with the time point of the exudative DAD stage in pulmonary pathology, and the turning point

235 of both neutralizing activity and T-cell responses in immunological dynamics. Longitudinal
236 VR values after respiratory support may be a suitable practical index for stratifying patients
237 with severe COVID-19 and predict successfully discontinued outcome.

238 **List of abbreviations**

239 ACE2: angiotensin-converting enzyme 2

240 ARDS: acute respiratory distress syndrome

241 AUC: area under ROC curve

242 BMI: body mass index

243 COVID-19: Coronavirus disease 2019

244 DAD: diffuse alveolar damage

245 Cstat: static lung compliance

246 FiO₂: the fraction of inspired oxygen

247 IBW: ideal body weight

248 ICU: intensive care unit

249 MERS-CoV: middle east respiratory syndrome coronavirus

250 MV: minute ventilation

251 PaCO₂: the partial pressure of carbon dioxide

252 PaO₂: the partial pressure of oxygen

253 PCR: polymerase chain reaction

254 PEEP: positive end-expiratory pressure

255 Pplat: plateau pressure

256 P/F: $\text{PaO}_2 / \text{FiO}_2$

257 ROC: receiver operating characteristic

258 SARS-CoV: severe acute respiratory syndrome coronavirus

259 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

260 V_D/V_T : dead space fraction

261 VR: ventilatory ratio

262 VT: tidal volume

263 **Declarations**

264 **Ethics approval and consent to participate**

265 This study was conducted under the approval of the Institutional Review Board of Osaka City

266 University (#2020-003) and the Clinical Research Ethics Committee of the Osaka Municipal

267 Hospital Organization (#2005020), Osaka, Japan.

268 **Consent for publication**

269 Not applicable.

270 **Availability of data and materials**

271 The datasets used and analyzed during the current study are available in Microsoft Excel files
272 titled 'Supplement Table 1 – 4'.

273 **Competing interests**

274 The authors declare that they have no competing interests.

275 **Funding**

276 This work was funded by Japan Agency for Medical Research and Development (AMED)
277 under Grant number JP20wm0125003 (Yasutoshi Kido), JP20he1122001 (Yasutoshi Kido),
278 JP20nk0101627 (Yasutoshi Kido), and JP20jk0110021 (Yu Nakagama). This work was also
279 supported by JSPS KAKENHI Grans Number JP21441824 (Natsuko Kaku). We also receive
280 the COVID-19 Private Fund (to the Shinya Yamanaka laboratory, CiRA, Kyoto University).
281 We received support from Osaka City University's "Special Reserves" fund for COVID-19.

282 **Authors' contributions**

283 N Kaku, M Shirano, and Y Kido designed the concept of the study. N Kaku, S Shinomiya, K
284 Yamazaki, K Shimazu, and Y Maehata, and R Morita performed the data acquisition. N Kaku,
285 Y Nakagama, Y Nitahara, and Y Kido assessed the quality of the study and performed the
286 analysis and interpretation. N Kaku, Y Nakagama, and Y Kido wrote the manuscript, and the
287 other authors made substantial revisions and edits. All authors read and approved the final
288 manuscript.

289 **Acknowledgements**

290 I am grateful to FORTE science communications for the manuscript revision. I would like to
291 thank the members of Osaka City General Hospital, where the main results of this paper were
292 obtained, especially Dr. T Nishida and Dr. T Shigemoto. I would also like to take this
293 opportunity to thank Dr. T Akamine, Dr. E Kataoka-Nakamatsu, Dr. R Uchida, and Dr. Y
294 Morimoto for their kind supports.

295 **Figure 1. Dynamics of ventilatory ratio, PaCO₂, and minute ventilation from 2 hours (day 0)**

296 **to day 6 after initiation of respiratory support.** Longitudinal daily values of ventilatory ratio
297 (VR) (a), PaCO₂ (b), and minute ventilation (c) from 2 hours (day 0) after initiation of
298 respiratory support to the following 6 days. The failed to discontinue group presented as the
299 solid triangles and solid lines, and the successfully discontinued group presented as the
300 opened circles and the dashed lines. Each marker placed on the median value, and each error
301 bar meant the 95% confidential interval. Statistical analysis determined the differences
302 between the failed to discontinue and successfully discontinued groups on each day by Mann-
303 Whitney test. * p -value < 0.05

304 **Figure 2. Receiver operating characteristics (ROC) curves for VR on days 0–4 after initiation**

305 **of respiratory support.** The prognostic ability of VR on the individual day was evaluated by
306 ROC curve analysis. A failed to discontinue outcome was analyzed as positive. The area under

307 the ROC curve (AUC) maximized on day 4 after initiation of respiratory support at 0.748,
308 which indicates moderate accuracy. The standard error was 0.091, 95% confidential interval
309 was 0.570 to 0.927, and the p -value was 0.019 (Table 2). The cut-off value for a maximum
310 diagnostic performance with a sensitivity of 0.667 and a specificity of 0.762 was $VR > 1.56$.

311 **Supplement Table 1.** Detailed information of demographic data, disease course, and
312 respiratory variables.

313 **Supplement Table 2.** Raw data of ventilatory ratio from 2 hours (day 0) to day 6 after initiation
314 of respiratory support.

315 **Supplement Table 3.** Raw data of PaCO₂ from 2 hours (day 0) to day 6 after initiation of
316 respiratory support.

317 **Supplement Table 4.** Raw data of minute ventilation from 2 hours (day 0) to day 6 after
318 initiation of respiratory support.

319 **References**

- 320 1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.
321 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
322 Proven Protease Inhibitor. *Cell*. 2020 Apr;181(2):271-280.e8.
- 323 2. Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-
324 19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York
325 City. *Mod Pathol*. 2020 Nov;33(11):2156–68.
- 326 3. Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: A pathological
327 review for clinicians. *Respiratory Medicine*. 2021 Jan;176:106239.

- 328 4. Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-
329 19: a brief summary and comparison of severe acute respiratory infections caused by
330 three highly pathogenic human coronaviruses. *Respir Res.* 2020 Dec;21(1):224.
- 331 5. Cardinal-Fernández P, Lorente JA, Ballén-Barragán A, Matute-Bello G. Acute
332 Respiratory Distress Syndrome and Diffuse Alveolar Damage. *New Insights on a*
333 *Complex Relationship.* *Annals ATS.* 2017 Jun;14(6):844–50.
- 334 6. Sinha P, Fauvel NJ, Singh P, Soni N. Analysis of ventilatory ratio as a novel method to
335 monitor ventilatory adequacy at the bedside. *Crit Care.* 2013;17(1):R34.
- 336 7. Sinha P, Fauvel NJ, Singh S, Soni N. Ventilatory ratio: a simple bedside measure of
337 ventilation. *British Journal of Anaesthesia.* 2009 May;102(5):692–7.
- 338 8. Sinha P, Calfee CS, Beitler JR, Soni N, Ho K, Matthay MA, et al. Physiologic Analysis
339 and Clinical Performance of the Ventilatory Ratio in Acute Respiratory Distress
340 Syndrome. *Am J Respir Crit Care Med.* 2019 Feb;199(3):333–41.
- 341 9. Sinha P, Singh S, Hardman JG, Bersten AD, Soni N. Evaluation of the physiological
342 properties of ventilatory ratio in a computational cardiopulmonary model and its clinical
343 application in an acute respiratory distress syndrome population. *British Journal of*
344 *Anaesthesia.* 2014 Jan;112(1):96–101.
- 345 10. Sinha P, Sanders RD, Soni N, Vukoja MK, Gajic O. Acute Respiratory Distress
346 Syndrome: The Prognostic Value of Ventilatory Ratio—A Simple Bedside Tool to
347 Monitor Ventilatory Efficiency. *Am J Respir Crit Care Med.* 2013 May
348 15;187(10):1150–3.
- 349 11. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of
350 Ventilator-Free Days in Critical Care Research. 2019;200(7):9.
- 351 12. Ministry of Health, Labour and Welfare. National Health and Nutrition Survey 2020
352 [Japanese]. 2021. <https://www.mhlw.go.jp/content/10900000/000687163.pdf>.
353 Accessed 20 Jul 2021.
- 354 13. Acute Respiratory Distress Syndrome: The Berlin Definition. *JAMA.* 2012 Jun;307(23).
- 355 14. Bösmüller H, Matter M, Fend F, Tzankov A. The pulmonary pathology of COVID-19.
356 *Virchows Arch.* 2021 Jan;478(1):137–50.

- 357 15. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. Pulmonary Pathology of Early-Phase 2019
358 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.
359 *Journal of Thoracic Oncology*. 2020 May;15(5):700–4.
- 360 16. Pernazza A, Mancini M, Rullo E, Bassi M, De Giacomo T, Rocca CD, et al. Early
361 histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen.
362 *Virchows Arch*. 2020 Nov;477(5):743–8.
- 363 17. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al.
364 Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with
365 severe capillary congestion and variegated findings in lungs and other organs suggesting
366 vascular dysfunction. *Histopathology*. 2020;77(2):198–209.
- 367 18. Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction
368 of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild
369 disease in COVID-19 patients. *Cell Reports*. 2021 Feb;34(6):108728.
- 370 19. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigail J, et al. A longitudinal study of
371 SARS-CoV-2-infected patients reveals a high correlation between neutralizing
372 antibodies and COVID-19 severity. *Cell Mol Immunol*. 2021 Feb;18(2):318–27.
- 373 20. Endo H, Ohbe H, Kumasawa J, Uchino S, Hashimoto S, Aoki Y, et al. Conventional risk
374 prediction models fail to accurately predict mortality risk among patients with
375 coronavirus disease 2019 in intensive care units: a difficult time to assess clinical severity
376 and quality of care. *J Intensive Care*. 2021 Jun;9(1):42.
- 377 21. Diehl J-L, Peron N, Chocron R, Debuc B, Guerot E, Hauw-Berlemont C, et al.
378 Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a
379 hypothesis-generating study. *Ann Intensive Care*. 2020 Dec;10(1):95.
- 380 22. Grieco DL, Bongiovanni F, Chen L, Menga LS, Cutuli SL, Pintaudi G, et al. Respiratory
381 physiology of COVID-19-induced respiratory failure compared to ARDS of other
382 etiologies. *Crit Care*. 2020 Dec;24(1):529.
- 383 23. Avdeev SN, Yaroshetskiy AI, Tsareva NA, Merzhoeva ZM, Trushenko NV, Nekludova
384 GV, et al. Noninvasive ventilation for acute hypoxemic respiratory failure in patients
385 with COVID-19. *The American Journal of Emergency Medicine*. 2021 Jan;39:154–7.

Table 1. Demographic data, disease course, and respiratory variables.

	All patients (n=40)	Filed to discontinue (n=14)	Successfully discontinued (n=26)	p-value
Patient characteristics				
Age - year	70 (59–76)	75 (67–81)	67 (56–74)	0.027 *
Male - no (%)	34/40 (85.0)	11/14 (78.6)	23/26 (88.5)	0.403
BMI - kg/m ²	25.0 (22.0–29.0)	24.0 (22.0–26.0)	25.0 (22.0–30.0)	0.303
Diabetes - no (%)	18/40 (45.0)	7/14 (50.0)	11/26 (42.3)	0.641
Hypertension - no (%)	21/40 (52.5)	9/14 (64.3)	12/26 (46.2)	0.273
Disease course				
Days from onset to O ₂ requirement	7 (6–9)	8 (6–10)	7 (6–8)	0.219
Days from onset to respiratory support	8 (7–10)	10 (8–12)	8 (7–10)	0.283
Days of respiratory support	11 (5–18)	19 (14–28)	7 (4–12)	<0.001 *
ICU mortality - no (%)	10/40 (25.0)	10/14 (71.4)	0/26 (0.0)	<0.001 *
Respiratory variables				
Minute ventilation - L	8.0 (6.3–9.0)	8.0 (5.8–9.0)	8.0 (6.8–11.3)	0.303
Tidal volume - mL/kg/ IBW	7.2 (6.2–7.9)	7.2 (6.2–7.8)	7.2 (6.2–8.1)	0.763
set PEEP - cmH ₂ O	9.0 (7.3–10.0)	10.0 (8.0–10.5)	8.0 (5.0–10.0)	0.409
Pplat - cmH ₂ O	22.0 (20.0–25.0)	22.0 (18.0–24.3)	22.0 (20.0–25.0)	0.508
Cstat - mL/cmH ₂ O	33.3 (27.8–44.5)	37.9 (28.0–46.1)	33.2 (26.8–38.2)	0.576
PaCO ₂ - mmHg	41.4 (36.8–49.3)	43.5 (36.5–48.7)	39.7 (36.9–50.3)	0.774
PaO ₂ /FiO ₂ ratio	173.5 (126.5 – 248.0)	170.0 (123.8–240.0)	177.0 (128.8–256.8)	0.774
PaO ₂ /FiO ₂ class				
>300 - no (%)	3/40 (7.5)	2/14 (14.3)	1/26 (3.8)	0.238
200-300 - no (%)	10/40 (25.0)	2/14 (14/3)	8/26 (30.8)	0.251
100-200 - no (%)	22/40 (55.0)	9/14 64.3)	14/26 (53.8)	0.524
<100 - no (%)	5/40 (12.5)	1/14 (7.1)	3/26 (11.5)	0.659
Ventilatory ratio	1.5 (1.3–2.0)	1.5 (1.3–1.9)	1.5 (1.3–2.1)	0.797

Continuous variables are shown as medians with quadrants, and nominal variables are shown as percentages of the total. Asterisks indicate statistical significance. IBW ideal body weight, PEEP positive end-expiratory pressure, Pplat plateau pressure, Cstat static lung compliance




Figure 1. Dynamics of ventilatory ratio, PaCO₂, and minute ventilation from 2 hours (day 0) to day 6 after initiation of respiratory support.




Figure 2. Receiver operating characteristics (ROC) curves for VR on days 0–4 after initiation of respiratory support.

Table 2. The parameters of the area under ROC curve on each day after initiation of respiratory support.

After initiation of respiratory support	Area	Standard error	95% CI	<i>p</i> -value
2 hours (day 0)	0.527	0.096	0.339 to 0.714	0.789
Day 1	0.520	0.112	0.301 to 0.738	0.854
Day 2	0.659	0.100	0.463 to 0.854	0.120
Day 3	0.678	0.100	0.483 to 0.872	0.074
Day 4	0.748	0.091	0.570 to 0.927	0.019 *

The parameters of the area under ROC curve (shown in Figure 2) on each day after initiation of respiratory support are described. An asterisk indicates statistical significance. ROC receiver operating characteristics, CI confidential interval